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Abstract miRNAs act as important regulators of gene
expression by promoting mRNA degradation or by atten-
uating protein translation. Since miRNAs are stably
expressed in bodily fluids, there is growing interest in
profiling these miRNAs, as it is minimally invasive and
cost-effective as a diagnostic matrix. A technical hurdle in
studying miRNA dynamics is the ability to reliably extract
miRNA as small sample volumes and low RNA abundance
create challenges for extraction and downstream applica-
tions. The purpose of this study was to develop a pipeline
for the recovery of miRNA using small volumes of
archived serum samples. The RNA was extracted
employing several widely utilized RNA isolation kits/
methods with and without addition of a carrier. The small
RNA library preparation was carried out using Illumina
TruSeq small RNA kit and sequencing was carried out
using Illumina platform. A fraction of five microliters of
total RNA was used for library preparation as quantifica-
tion is below the detection limit. We were able to profile
miRNA levels in serum from all the methods tested. We
found out that addition of nucleic acid based carrier
molecules had higher numbers of processed reads but it did
not enhance the mapping of any miRBase annotated
sequences. However, some of the extraction procedures
offer certain advantages: RNA extracted by TRIzol seemed
to align to the miRBase best; extractions using TRIzol with
carrier yielded higher miRNA-to-small RNA ratios.
Nuclease free glycogen can be carrier of choice for miRNA
sequencing. Our findings illustrate that miRNA extraction
and quantification is influenced by the choice of method-
ologies. Addition of nucleic acid- based carrier molecules
during extraction procedure is not a good choice when
assaying miRNA using sequencing. The careful selection
of an extraction method permits the archived serum sam-
ples to become valuable resources for high-throughput
applications.
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Introduction
miRNA is a functionally important class of small, non–
protein coding RNA, 19–24 nucleotides in length, that are
post-transcriptional regulators of gene expression [1].
miRNAs act as important regulators of gene expression by
promoting mRNA degradation or by attenuating protein
translation [2]. It has been suggested that miRNA can
potentially regulate every aspect of cellular activity such as
cell development, differentiation, proliferation, cell death,
stress reaction, fat metabolism, insulin secretion and car-
cinogenesis [3–5]. A single miRNA can regulate hundreds
of mRNAs by recognizing complementary sequences in the
30UTRs of their target mRNA, and multiple miRNAs can
regulate an individual mRNA [6]. Current estimates
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indicate that more than one-third of the cellular transcrip-
tome is regulated by miRNAs [7]. miRNAs have been
found in tissues, serum/plasma, and other body fluids in a
stable form that is protected from endogenous RNase
activity. miRNA expression in biofluids, such as serum,
plasma, urine or cerebrospinal fluid, is a rapidly expanding
area of research [8]. miRNAs in circulation are thought to
contribute to the normal functioning of circulatory and
immune systems [9, 10] and have been proposed as can-
didate biomarkers of health/disease status [11, 12]. Results
of another study by Keller and coworkers [13] strengthen
the potential of blood-borne miRNAs as biomarkers. The
use of serum or plasma reduces variables and possibly
allows the detection of a more concentrated disease-related
miRNome by decreasing the background expression of
miRNAs from blood cells.
The measurement and exact quantification of miRNAs
from serum are hampered by low yields of RNA due to
its low concentration (0.1–1 ng/ml) [14]. However,
miRNA is considered stable even after subjected to severe
conditions such as freeze–thaw cycles and storage con-
ditions, as well as changes in the pH levels [15, 16]. In
contrast, synthetic, unbound, free-circulating miRNA
degrades rapidly [17]. The profiles of miRNA are pre-
served up to 10 years in archived serum [18], and it was
recently published that the miRNA and DNA may be
frozen up to 40 years without significant degradation
[19, 20]. A technical hurdle in studying the dynamics of
gene expression is the ability to reliably extract miRNA
from these compromised biological samples. However, a
number of commercial extraction kits have recently
become available that seek to optimize the extraction of
small RNAs, either in conjunction with full length total
RNA or as a fraction enriched for small RNAs. Histori-
cally, genome-wide analysis of miRNA expression has
been performed through microarrays [21, 22], but the
effort is now largely based on sequencing [23–26]. Next-
Generation Sequencing (NGS) technology has quickly
emerged as a preferred method for studying miRNA
expression. Sequencing provides the opportunity to
examine all miRNAs simultaneously and has the potential
to identify novel miRNAs. Thus, isolation of miRNAs
must be optimized for sequencing analysis.
In this study, we evaluated different extraction pro-
cedures, with and without addition of a carrier, on serum
‘‘test samples’’ that were obtained from the Department
of Defense Serum Repository (DoDSR). These speci-
mens are linked with the Defense Medical Surveillance
System (DMSS) data and are augmented by epidemio-
logical studies for military and operational relevance,
and upon additional approval, the samples can be applied
for research purposes. The rich details related to military
service that have been collected provide health
professionals with unique opportunities to utilize these
archived samples to find solutions for both demograph-
ical groups and individuals. It is important to optimize
the different aspects of sample management, such as
sample storage conditions and extraction procedures, and




The serum samples were obtained from the DoDSR where
they were stored at -30 C. These samples were called
‘‘test samples’’ and were used to conduct a pilot study with
the purpose of determining suitable methods for these
compromised samples before setting up a larger study. In
the current study, a subset of samples was thawed on ice,
pooled, and divided into 350 lL aliquots, frozen and stored
at -80 C to be used in extractions as ‘‘pooled’’ samples
(Fig. 1) and we used a subset of independent, archived
serum samples as received from the DoDSR, calling this
set ‘‘unpooled samples.’’ For each extraction method,
individual 350 lL sample aliquots were thawed, followed
by addition of initial denaturant from the respective kits.
We used triplicates samples for each extraction therefore a
total of 36 samples were generated from the study. All
procedures used 350 lL of serum for miRNA extractions
except the Qiagen miRNeasy Mini Kit, where 200 lL of
sample was used per extraction.
RNA extraction
Different miRNA extraction methods were evaluated
with either unpooled or pooled serum samples used in
triplicate per extraction method. The extraction methods
TRIzol Reagent (Invitrogen, Life Technologies, Grand
Island, NY, USA) and TRIzol LS Reagent (Invitrogen)
were tested with or without a different carrier, such as
glycogen (Invitrogen), bacteriophage MS2 (Roche,
Basel, Switzerland) and yeast tRNA (Invitrogen).
Extractions were also performed using the miRNeasy
Mini Kit (Qiagen, Valencia, CA, USA). Other extraction
methodologies that were tested only on the unpooled
samples were the mirVANA miRNA Isolation Kit
(Ambion, Life Technologies, Thermo Fisher Scientific,
Waltham, MA, USA), the ExoQuick Exosome precipi-
tation (System Biosciences, Inc., Mountain View, CA,
USA) extraction in conjunction with the TRIzol proce-
dure, and the ExoQuick Exosome precipitation in com-
bination with mirVANA miRNA Isolation Kit. The
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detailed study plan is shown in Fig. 1. The description of
each extraction method is explained below.
TRIzol
TRIzol extractions were conducted according to the man-
ufacturer’s protocol (Invitrogen). Briefly, 700 lL of TRIzol
was added to 350 lL of serum followed by incubation at
room temperature for 5 min. Chloroform (Sigma-Aldrich,
St. Louis, MO, USA) was added, and the samples were
vortexed and incubated for 5 min at room temperature
followed by centrifugation at 12,0009g for 15 min at 4 C.
The aqueous phase containing RNA was transferred to a
new tube and isopropanol (Fisher-Scientific, Thermo
Fisher Scientific, Waltham, MA, USA) was added. The
samples were incubated at room temperature for 10 min
followed by centrifugation at 12,000xg for 15 min at 4 C.
The pellet was washed with 75 % Ethanol (Sigma-
Aldrich), air-dried and resuspended in 20 lL nuclease-free
water (Ambion). For addition of carriers, 2 lL of glycogen
(5 lg/lL), 1 lL of bacteriophage MS2 RNA (500 ng/lL)
or 1 lL of yeast tRNA (500 ng/lL) were added during the
isopropanol precipitation of the extraction procedure.
TRIzol LS was used instead of TRIzol in the procedure
using the glycogen carrier.
mirVANA kit
The samples were processed using the mirVANA miRNA
Isolation Kit following the manufacturer’s protocol.
ExoQuick exosome precipitation followed by TRIzol
extraction
The samples were processed using the ExoQuick Exosome
precipitation method by adding 90 lL of ExoQuick solu-
tion (System Biosciences, Inc.) and incubating overnight at
4 C. The samples were centrifuged at 1500xg for 30 min
at room temperature and the supernatant was aspirated,
followed by centrifugation of the pellet at 1500xg for
5 min at room temperature to remove all traces of residual
Exoquick solution. The pellet was dissolved in 350 lL of
TRIzol reagent and the TRIzol extraction procedure was
followed.
miRNeasy kit
The miRNeasy Mini Kit was used to extract miRNA and
total RNA following the manufacturer’s protocols.
miRNA quality control
The quality of the RNA was evaluated by the Bioanalyzer
2100 instrument (Agilent, Santa Clara, CA, USA) using the
small RNA chip (Agilent) according to the manufacturer’s
protocol.
Small RNA sequencing
Small RNA libraries were prepared using the TruSeq
Small RNA Sample Preparation kit (Illumina, San Diego,
Fig. 1 Experimental set-up:
Multiple pooled serum samples,
as well as an independent set of
unpooled serum samples, were
used for RNA extractions using
multiple methods
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CA, USA) following the manufacturer’s instructions. A
fraction of five microliter of total RNA was used for
library preparation as quantification is below the detection
limit. Five microliters of total RNA was ligated with 30
and 50 adaptors followed by reverse transcription with
SuperScript II Reverse Transcriptase (Invitrogen) and
unique indexes were introduced during PCR amplification
for 15 cycles. A multiplexed pool consisting of equimolar
amounts of small RNA-derived libraries was prepared.
The 140–150 nt region containing the microRNA fraction
of the library was excised from a 6 % polyacrylamide gel
after electrophoresis, ethanol-precipitated and quantified.
The samples were subsequently sequenced on the Illu-
mina HiScan SQ instrument using 50 ? 7 (index)
sequencing cycles.
Sequencing data analysis
Our data analysis pipeline (Fig. 2) performs preprocessing
of reads for quality assessment, quality filtering, and
adaptor trimming of raw reads, then implements sequence
read alignments against reference genome assembly,
miRNA quantification, and lastly, executes expression and
functional analyses.
The standard open source tool CASAVA 1.8.2 (Illu-
mina, Inc.) was used to preprocess raw base calls and de-
multiplex samples. Reads were processed further for
quality assessment, quality filtering, and adaptor trimming,
and quality filtered again using a Phred quality score
threshold of 20. The ligated adaptor sequences were trim-
med, leaving a minimum overlap of five bases while
Fig. 2 Pipeline for data analysis: Raw reads are preprocessed for
quality assessment, quality filtering and adaptor trimming of raw
reads, followed by sequence read alignment against reference genome
assembly and miRNA quantification, and lastly, expression and
functional analysis. The quality control step generates quality check
reports in HTML/PDF format. The reports highlight the per sequence
quality scores, sequence base quality scores, sequence GC and Kmer
content, duplicate sequences, overrepresented sequences and overall
sequence length distribution. The alignment step generates alignment
files and HTML files with mapping statistics for the percentage of
reads mapped out of total number of reads against reference genome/
miRBase. This also generates the count matrix of total read count for
each annotated miRNA/gene for each sample in text file format
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allowing an error rate of 0.1 using CutAdapt 1.2.1. (Martin
2011). Additional filtering was also applied to retain
sequences with a minimum length of 15 base pairs and to
discard sequences of fewer than 15 base pairs in length.
The average read length distribution across protocols per
purification method was further statistically assessed using
Pearson Chi Square test using read length as bins for each
protocol.
Using the short read aligner Bowtie 1.0.0 [27], fil-
tered sequence reads were aligned to the Human ref-
erence genome assembly humanv37 from Ensembl [28],
and the best hits to the genome were identified using
BEDtools 2.17. Small RNA species were annotated by
mapping with the reference gene feature annotation
table from the Ensembl database. Quantification/en-
richment reads for miRNAs were first aligned to the
Rfam RNA families database to filter other small RNA
species, and then reads were mapped for small RNA
annotation against reference mature/precursor hg19_-
mature RNA sequences from the miRBase (miRbase
19) database [29–32]. The miRNA read count matrix
for each sample was generated using open source tools
Picard 1.84 (http://broadinstitute.github.io/picard),
SAMtools 0.1.19 [33], BEDtools 2.17 [34] and shell/
Perl/R scripts [35]. The miRNA count was normalized
using TMM normalization method using R Biocondutor
package edgeR. The Excel CORREL function that
calculates the Pearson Product-Moment was used to
calculate the correlation coefficient to determine the
relationship between replicates isolated using different
extraction methods. The sequencing data was submitted
to the Gene Expression Omnibus (GEO) and raw reads
are available through Sequence Read Archive (SRA)
using series #GSE80274 and Platform ID:GPL15456.
Results and discussion
The purpose of our study was to develop a method of RNA
extraction from archived serum samples stored at -30 C
to obtain sufficient yields and acceptable quantities of
miRNA for NGS. miRNA has been shown to be present in
twelve body fluids tested [36], and higher miRNA con-
centrations have been observed in serum samples as com-
pared to plasma samples [37]. Serum is known to contain a
considerable amount of stable miRNA [15], and in recent
years, researchers have proposed that serum miRNAs could
possibly serve as a source of novel biomarkers for
uncovering various diseases [11, 12]. Considering the
collection and storage of serum samples at the DoDSR and
the stability of miRNA, we can potentially use these
samples for biomarker discovery related to diseases of
military relevance.
RNA extraction procedures
The method used to purify RNA impacts both yield and the
spectrum of RNA isolated [38, 39]. miRNA molecules
behave physically and chemically different from the larger
RNA molecules, and their quantitative recovery requires
optimization of existing total RNA isolation procedures. To
date, most RNA and miRNA extraction methods use a
phenol: chloroform-based extraction technique often
facilitated by the addition of guanidinium thiocyanate, and
the most commonly used reagent in this technique is
TRIzol [40]. This reagent relies on isopropanol precipita-
tion and centrifugation sedimentation. Although TRIzol
isolation is a widely employed method, it has been reported
that TRIzol favors specific miRNAs and fails to isolate
those low in guanine and cytosine [41]. Furthermore, if the
RNase-containing denaturing reagents are not removed
completely in the final RNA preparation, they can interfere
with the efficiency of downstream applications. To remove
serum RNases, many commercial kits such as the Qiagen
miRNeasy Mini Kit and mirVANA miRNA Isolation Kit
use filtering agents that remove the RNA inhibitors during
the extraction process. Therefore, it is important to choose
an extraction method which minimizes the carry-over of
such inhibitors while maximizing the RNA yield. Several
previous reports have compared miRNA extraction kits.
Notably, Kroh et al., have tested variations of two extrac-
tion kits for plasma and serum samples: Ambion’s mir-
VANA PARIS (with addition of an extra organic extraction
step), and the Qiagen miRNeasy Mini Kit (with a protocol
modified to use 10 volumes of Qiazol reagent per volume
of plasma or serum). They showed that although both
protocols have proven to be effective, the Qiagen protocol
appears to produce two- to three-fold greater RNA yield
[42]. Likewise, Li and colleagues evaluated the perfor-
mances of the Qiagen miRNeasy kit, the Ambion mir-
VANA PARIS kit and the Total RNA Purification Kit
(Norgen Biotek, Canada) [43]. They concluded that RNAs
isolated by the Qiagen or Ambion kits had better quality (in
terms of the percentage of miRNAs in the small RNA
fraction) than those extracted with the Norgen kit. We
tested the TRIzol procedure, the mirVANA miRNA Iso-
lation Kit, and the Qiagen miRNeasy Kit in our study,
noting that these kits have been used to assess plasma and
cerebrospinal fluid samples [44]. miRNA are also known to
exist in exosomes [45], and we utilized the ExoQuick
Exosome precipitation method along with TRIzol
procedure.
Serum has low amounts of total RNA, and small RNA
only constitutes 0.4–0.5 % of this total [46]. To maximize
the yield of isolated RNA that includes small RNA, we
added known quantities of carrier molecules for precipi-
tation of total RNA. Glycogen, yeast tRNA, and
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bacteriophage MS2 RNA were added as carriers during the
TRIzol extraction procedure.
The use of glycogen in RNA isolation has been reported
previously [47] to prepare samples for subsequent real-time
PCR analysis of miRNA levels. Glycogen has been
reported to be an effective carrier for certain procedures:
extraction of 50 lL of plasma using the miRNeasy Mini
Kit with the addition of 5 lg of glycogen resulted in the
highest recovery of endogenous miRNA [48]. A study of
RNA extraction of plasma by different methods found that
addition of glycogen seemed to be beneficial for some, but
not all, isolation methods tested [44]. Addition of bacte-
riophage RNA has been observed to improve miRNA
quantification [49], but more studies are needed to
demonstrate its reliability. Yeast tRNA [50] has been used
for isolation of microscale RNA, and the GeneChip RNA
control RNA in the analyses confirms that addition of
carrier tRNA does not cause detectable distortion in global
amplification [51].
Many studies have compared different methods for
miRNA extraction [44]. TRIzol-chloroform extraction has
been shown to be the most suitable for large-scale exper-
iments [52] and allowed the highest recovery of low
molecular weight RNA [53]. Recently, studies of plasma
miRNA extraction methodologies comparing TRIzol to
column-based procedures revealed that the Qiagen miR-
Neasy Serum/Plasma Kit rendered more concentrated RNA
[50]. This study also reported that the addition of 1 lg/mL
yeast tRNA gave better results than 10 lg/mL of yeast
tRNA. In all the protocols investigated, we were able to
save the DNA phase during extraction. Maximizing DNA
and total RNA retrieval from the same specimen is very
useful when extracting samples of limited availability.
The samples obtained from the DoDSR cannot be con-
trolled for the initial sample processing and storage con-
ditions; therefore, the purpose of this study was to test for
maximum RNA yield using the different isolation methods
available.
RNA quality and yield
There is not a method currently available that can evaluate
the exact amount or quality of small RNA. Extracellular
miRNAs are less than 1 % of the total RNA recovered [40],
and since both total extracellular miRNA and RNA are
recovered, the miRNA concentration is prone to overesti-
mation if total RNA is degraded during the isolation pro-
cess. Therefore, standard methods for measurement of the
RNA yield and quality are not adequate for biofluid sam-
ples. The quantification of miRNAs in blood is further
complicated by the high protein content and low RNA
concentrations in plasma and serum. Even with the use of
carrier molecules to improve isolation [49, 54], yields are
often at or below the threshold for accurate quantification
by spectrophotometric analyses [42]. Spectrophotometric
measurement of RNA at OD 260 nm becomes impossible
for some of these samples because of the presence of
carrier RNA. Even without using carrier in the extraction,
the concentration of the RNA obtained was still too low for
spectrophotometric analysis since each of our extracts had
an RNA concentration of less than 10 ng/lL (data not
shown). Recently, plasma samples were shown to yield
quantifiable RNA concentrations (only when a carrier was
not added during the extraction procedure) when the
plasma input was raised to 6 ml [55] using Qiagen miR-
Neasy Serum/Plasma Kit for extraction. When the miRNA
yield and concentration are sufficient, quality assessment of
the extraction method can be performed by capillary
electrophoresis using the Agilent 2100 Bioanalyzer. The
TRIzol extracts had ratios of miRNA to small RNA at less
than 40 % from pooled as well as unpooled samples
(Fig. 3a). Addition of carrier during TRIzol extraction
increased the miRNA to small RNA ratio except when
carrier yeast tRNA was used in extracting the pooled
samples. ExoQuick Exosome precipitation prior to the
TRIzol procedure did not yield greater amounts of miRNA
as compared to the TRIzol procedure alone. The miRNeasy
Mini Kit appeared to guarantee a constant amount of
miRNA extracted across all corresponding samples.
The Agilent 2100 Bioanalyzer system quantifies RNA
using an algorithm based on ribosomal RNA detection and
assigns an RNA Integrity Number (RIN) to demonstrate
RNA quality. However, this algorithm is not applicable to
quantification of miRNA extracted from serum samples.
Recently, it was reported that the percentage of RNA
fragments[200 nt in a sample (termed the ‘‘DV 200’’
value) is a more reliable predictor of RNA quality when
analyzing highly-degraded RNA sample quality as com-
pared to the traditional integrity score or value [56].
There are conflicting opinions on whether biological
carrier RNAs might be responsible for non-specific
hybridization or amplification in downstream analytics
[44]. Additionally, degradation of carrier RNA during
RNA isolation could lead to inaccurate quantification for
downstream applications. It is important to use highly
purified carrier or co-precipitant. We did not observe any
smearing in the extracts isolated using glycogen, whereas
we detected a smear for the extracts where MS2 RNA and
yeast tRNA were used as carrier molecules (Fig. 3b),
reflecting carrier degradation during precipitation or
background isolated with the extraction procedure. The
examination of individual miRNAs by qRT-PCR is rec-
ommended but was not attempted for our extracts because
of limited availability.
It is known that RNA yield is affected by the specific
purification methods used [53, 57]. The choice of
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methodology for miRNA extraction from bodily fluids
depends mainly on the available initial volume of samples
and the methods for subsequent analyses, and most of the
variables are study- and investigator-dependent. Our data
shows small RNA has been preserved in the DoDSR
archived samples and each protocol tested was successful
in extracting miRNA.
Small RNA cDNA library preparation
Studies have attempted to detect plasma/serum miRNA
using microarrays and qRT-PCR [58]. Recently, there are
reports that miRNAs in the circulatory system have been
characterized using a deep-sequencing approach for serum
and plasma [59, 60]. The success of small RNA sequencing
depends most on the composition of the library being free
of undesirable degradation remnants or naturally abundant
short ribosomal RNA fragments [61]. Extractions of larger
volumes of plasma have yielded 35 ng of total RNA in
preparation for sequencing [55]. As per Illumina guideli-
nes, it is recommended to use the maximum amount of
total RNA (1 lg) in preparation for sequencing. Since we
could not determine quantities of small RNA, we prepared
our libraries with a fixed starting volume of extracted RNA.
We did not see a discrete band for the miRNA library, but
the library was size-selected for isolation and a High
Sensitivity DNA Assay on the Agilent 2100 Bioanalyzer
revealed that cDNA libraries of the correct size were
generated with adaptor-ligated constructs, which signified
the successful amplification of mature miRNAs. The
resulting small RNA library was pooled and loaded on a
flow cell in a random manner on the Illumina HiScan
sequencing run.
Sequencing results
Read mapping/annotation and expression profiling-
data processing
Our data analysis pipeline performs preprocessing of reads,
aligns sequence reads against reference genome assembly,
and quantifies miRNAs, followed by a quality control step.
The alignment step generates alignment files and HTML
files with mapping statistics for the percentage of reads
mapped out of total number of reads against the reference
genome/miRBase. Pooling has been used to examine the
general characteristics of the reads [62] and for this reason,
we used pooled samples in our study. We found similar
numbers of processed reads from pooled as well as
unpooled samples when TRIzol and miRNeasy methods
were utilized. The number of processed reads using each
procedure is shown in Fig. 4. TRIzol with glycogen had
comparable reads from the pooled (94,203 reads) as well as
unpooled (69,146 reads) samples. No consistency in pro-
cessed reads was observed between pooled and unpooled
samples when bacteriophage MS2 or yeast tRNA was
added. Yeast tRNA had 6 times greater processed reads
from pooled samples as compared to unpooled samples
whereas bacteriophage MS2 had around 5 times fewer
processed reads from pooled samples as compared to
unpooled samples. This indicates that the addition of
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Fig. 3 Small RNA analysis performed by using the Agilent 2100
Bioanalyzer and and the sequencing library preparation using
Illumina TruSeq Small RNA kit: a miRNA/sRNA ratio: Ratio of
miRNA molecules expressed as a portion of all small RNA molecules
(%) detected with the Agilent 2100 Bioanalyzer. b Electronic gel
image of small RNA library obtained using Illumina TruSeq Small
RNA kit for the unpooled samples where carrier was added to the
TRIzol extraction procedure
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carrier RNA can lead to non-uniformity in general. We
were not able to identify any study that has used carrier-
supplemented RNA for sequencing. The consistency in
similar amount of reads from glycogen supplemented
samples might be attributed to using TRIzol LS during
extraction and needs to be investigated. The TRIzol LS
differs from standard TRIzol in concentration and is for-
mulated to use with liquid samples such as serum. How-
ever, when quantifying digital gene expression, potential
modification of the carrier nucleic acid may result in sub-
sequent sequencing of carrier DNA or RNA [63]. Exosome
precipitation prior to RNA extraction yielded a lower
number of processed reads as compared to yields from
extraction by the TRIzol procedure without a carrier.
Furthermore, it has been stressed that the quantity of carrier
used is crucial in RNA yield, as carrier concentration can
mask the quantity of extracted RNA and affect the accu-
racy of the quantification and quality of the analysis [50].
Size distribution of small RNA
The miRNA profile was compared between different
extraction methods with and without, as well as before and
after, the addition of carrier (results from TRIzol extrac-
tions shown in Fig. 5), and we observed a read length of
20–25 nt from pooled serum samples (Fig. 5b). The num-
ber of sequences is significantly higher, i.e. 69,804 in
unpooled samples and 128,364 in pooled samples where
carrier yeast tRNA was added during the isolation proce-
dure. The TRIzol only procedure had 48,020 and 19,008
sequences from unpooled and pooled samples respectively.
The TRIzol with glycogen procedure had only 5620
sequences from unpooled samples which was lowest
among these different carriers. In case of pooled samples
TRIzol with MS2 had 9176 sequences, the lowest among
rest of the supplemented carriers. The addition of yeast
tRNA also yielded much larger-sized fragments, followed
by fragment sizes obtained using glycogen and bacterio-
phage MS2. However, from the unpooled samples
(Fig. 5a), the histogram shows the peak around 15–20 nt
read length, with and without carrier supplementation. The
method with addition of yeast tRNA gave the maximum
number of sequences. All other methods except the TRIzol
supplemented with yeast tRNA had read lengths from 15 to
30 nt, but the TRIzol with yeast tRNA had a larger range of
read length, 15–38 nt. Longer tRNA read lengths between
26 and 32 nt could be attributed to degraded fragments
because of carrier introduction during extraction procedure
or piwi-interacting RNA (piRNA), known to be longer in
length than miRNA [55]. It has been reported that the
normal range of miRNA is 18–24 nt [64], although most
are 22–23 nt [65].
Proportion of miRNAs
The count matrix of total read counts was generated for
each annotated miRNA. Reads were mapped using an
alignment mode that allows zero mismatches for the
readlength of 22 nt for high-quality read ends, and stringent
alignment options were selected in the aligner to obtain the
best alignments which trimmed 10 bases from the low-
quality (30) end of each read before alignment. The good
quality processed reads were aligned to mature miRBase
and only a proportion of sequences mapped to the database,
as shown in stacked bar plot (Fig. 6). The TRIzol extrac-
tion procedure gave the maximum percentage of aligned
reads, 90 % from unpooled samples and *62 % from
pooled samples. The un-aligned read fraction is shown as
the shaded area in the bar plot whereas white region is the
fraction of aligned sequences. The miRNeasy extractions
produced fewer than 17 % aligned reads from both of the
sample types. The mirVANA extraction procedure resulted
in 50 % of aligned sequences from unpooled samples. The
TRIzol extraction with yeast tRNA as a carrier yielded
Fig. 4 The total number of
reads: The reads processed after
quality assessment, filtering and
adapter trimming for the
unpooled as well as for the
pooled samples. The error bar
represents the standard error of
mean
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fewer than 25 % aligned sequences from pooled as well as
unpooled samples. TRIzol extraction with bacteriophage
MS2 carrier gave 36 % aligned sequences from both of the
sample types. Addition of glycogen during the extraction
procedure also led to aligned sequences of fewer than 44 %
from pooled and 35 % from unpooled samples. The per-
centage of reads mapped to miRBase shows 40–50 % from
pooled samples and 80–90 % from unpooled samples.
Most of the protocols, except miRNeasy, displayed
20–50 % higher percentage of reads mapping to miRBase
from unpooled samples in comparison to reads from pooled
samples. Although TRIzol with yeast tRNA and TRIzol
with MS2 yielded the maximum numbers of processed
reads, these extraction procedures produced the lowest
percentage of aligned sequences to miRBase, revealing that
degradation of the carrier RNA during extraction procedure
contributed to the small RNA isolated. The miRNA count
generated for the each sample is shown in Supplemental
Table 1. Correlation analysis of miRNA counts within each
extraction procedure was performed and replicates within
a Unpooled samples b pooled samples
Mean sequence length:
17.04 ± 3.36 bp
Mean sequence length:
18.32 ± 4.96 bp
Mean sequence length:
20.29 ± 5.55 bp
Mean sequence length:
26.82 ± 7.57 bp
Mean sequence length:
20.64 ± 6.35 bp
Mean sequence length:
21.51 ± 5.77 bp
Mean sequence length:
23.54 ± 5.64 bp
Mean sequence length:
25.66 ± 7.43 bp
Fig. 5 Read distribution plots, TRIzol with and without addition of carrier: Size distribution of total sRNA range from 15 to 37 nt. a Unpooled
serum samples. b Pooled serum samples
Fig. 6 Annotated miRBase sequences: Processed reads were aligned to miRBase and reads aligned are represented for a Unpooled serum
samples b Pooled serum samples
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the same extraction procedure had a very good correlation
coefficient ranging from 0.76 to 0.99. For the pooled
samples correlation coefficient between replicates was
ranging from 0.76 to 0.94 whereas the replicates from
unpooled samples had a correlation coefficient in a range
from 0.88 to 0.99. The correlation analysis across methods
was done on pooled samples and we found out that TRIzol
with ytRNA had no correlation with TRIzol, TRI-
zol ? glycogen, TRIzol ? MS2 and miRNeasy procedures
(coefficient 0.01–0.05). The correlation coefficient for
TRIzol with TRIzol ? MS2 (0.39), TRIzol ? glycogen
(0.89) and miRNeasy (0.66), respectively.While these
within and across method comparisons give some insights
into their relative performances, without ground-truth
knowledge of miRNA content in these degraded samples,
we would further like to separate the signal from the noise
in our future studies. This study is an exploratory phase for
detection miRNA from the samples stored in compromised
storage conditions and the data is promising, considering
the signal that may have noise in the form of false posi-
tives. The reads that were not mapped to miRBase might be
due to small RNAs in the samples that are not yet annotated
and to filtering out reads of shorter lengths from maximum
reads before mapping. Also, since RNAs are exposed to a
high content of RNases in serum, RNA released from
apoptotic cells, active release, or carriers could be degraded
into pieces with an equivalent size range that would
superimpose onto the length distribution profile.
RNA species count
More than 95 % of the reads from most of the unpooled
sample types were annotated with coding sequences. The
TRIzol with carrier yeast tRNA procedure had 81 % of the
reads in coding regions whereas TRIzol with MS2 had
92 % aligned to coding regions (data not shown). From the
pooled samples, 90 % of the reads were in the coding
regions for all the procedures tested. We did not observe an
increase in reads mapping to the tRNA as a result of the
extraction procedure including yeast tRNA as a carrier. The
coding RNA species were the largest proportion when
mapped to the genome, and furthermore, other RNA spe-
cies involved in many biological processes were identified
among the isolated RNAs. The proportions of the RNA
species other than coding RNA are shown in Fig. 7: long
intergenic non-coding RNA (lincRNA), miRNA, ribosomal
RNA (rRNA), followed by small nuclear (sn) RNA, small
nucleolar (sno) RNA, tRNA pseudogenes, and other non-
coding RNA. From unpooled samples, the proportion of
lincRNA ranged from 8 to 26 % with the TRIzol, mir-
VANA and Exosome precipitation with TRIzol extraction
procedures yielding the highest numbers. The proportion of
miRNA obtained from unpooled samples increased with
use of the TRIzol procedures where carrier was added
(Fig. 7a). For the pooled samples, the carrier did not result
in a dramatic increase in miRNA proportion (Fig. 7b). This
demonstrates again that there are a number of variables
associated at different steps, from sample collection
through data analysis.
Serum miRNA isolated in common by different
methods
We analyzed the associations among different replicates
extracted by different miRNA isolation methods, and all of
the samples were positively correlated to each other for
pooled as well as for unpooled samples. The correlation of
pooled samples ranged from 76 to 94 %, whereas for
unpooled samples, it ranged from 88 to 99 %. We found
that TRIzol with yeast tRNA gave a very poor correlation
for miRNA counts with the rest of the procedures, for
pooled as well as unpooled samples (data not shown). It has
been reported that the addition of carrier tRNA during
RNA or DNA extraction can lead to false positives during
hybridization-based assays due to carry over of contami-
nating nucleic acids [66]. We can identify miRNA isolated
using the TRIzol-only method and the modified TRIzol
methods that we assessed were sufficient for obtaining
miRNA reads from the serum ‘‘test samples.’’ Weber et al.,
[36] quantified detectable miRNA from plasma using
Qiagen qPCR assays and listed the top 20 most abundantly
expressed miRNA in plasma. The miRNA counts observed
from our data are presented in Supplemental Table 1.
Since we were interested in discovering whether dif-
ferent extraction methods yield extracts that share miR-
NAs, the assembled list from three replicates was utilized
to determine the common miRNAs among the extraction
procedures (Fig. 8a, b). From the unpooled samples, all of
the protocols shown in Fig. 8a produced 28 miRNAs in
common, whereas TRIzol with glycogen, TRIzol with
MS2, TRIzol with yeast tRNA, and miRNeasy protocols
share 356 common isolated miRNAs. As the Venn diagram
illustrates, the extraction with bacteriophage MS2 carrier
yielded the maximum number of miRNAs overlapping
with those from the rest of the procedures for both sets of
samples. The next protocol that showed maximum overlap
is miRNeasy, although the number of processed reads was
very low for this method. There were no unique miRNAs
detected from the TRIzol and TRIzol with glycogen
methods from pooled as well as unpooled samples. How-
ever, TRIzol with yeast tRNA had three unique miRNAs
among the pooled samples. From the pooled samples, all of
the protocols yielded a total of 949 miRNAs in common
with read counts C6.0 log2 counts per million (logCPM)
values (Fig. 8b). Excluding the TRIzol with glycogen
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protocol, the TRIzol-only, TRIzol with MS2, TRIzol with
yeast tRNA, and miRNeasy protocols still gave 407 miR-
NAs in common. Since the pooled ‘‘test samples’’ are
derived from a large pool, we expect to see an increase in
the number of common miRNAs obtained by all of the
extraction procedures. We further analyzed the data to
observe if there is any particular purification method that is
affecting enrichment of certain miRNA families. The
miRNA counts were TMM normalized and the expression
values for all miRNA families for the procedures used for
pooled samples is shown as Supplemental Table 2. The
miRNeasy extraction method had largest numbers of
Fig. 7 Reads aligned to other RNA species: The processed reads
were aligned to the Ensembl database and the percent of reads
aligning to different RNA species is shown. a Unpooled samples
b Pooled samples. Chi square comparisons for small RNA species
were significant at p value; considering the variability within
methods, Kruskal–Wallis rank sum analysis was performed.
Unpooled samples had Chi squared = 99.021, df = 11, p-
value = 2.79e–16 and pooled samples had Chi squared = 191.56,
df = 11, p-value\ 2.2e–16. The p-value turns out to be nearly zero
and thus rejecting null hypothesis and small RNA species population
are not identical in different methods
Fig. 8 Venn diagram representing number of miRNA isolated in
common: The miRNAs identified from the triplicate samples using
the different isolation procedures have been appended into one list
and compiled into a Venn diagram representing the common miRNAs
between the different isolation procedures a Unpooled samples
b Pooled samples
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miRNA’s (*40) that are not represented in samples when
compared to other methods. Some of the miRNA that were
not expressed in miRNeasy extraction method were miR-
606, miR-1290, miR586, miR577, miR384, miR297, miR-
5697, and miR-4328. Some of the miRNA families were
consistent among different procedures, such as miR-370,
miR4428, miR765, miR3168, miR5687, etc. with higher
expression numbers for logCPM threshold cutoff greater
than 6. The TRIzol with glycogen had lowest expression
for many of the miRNA with expression values lower than
6 logCPM threshold cutoff. In unpooled samples, only the
TRIzol extraction with addition of bacteriophage MS2
method yielded unique miRNAs [36].
Conclusion
The study of miRNAs in serum from the DoDSR has the
potential to reveal insights into diseases of military rele-
vance. The circulating miRNAs are stable for long periods
of time, but there remain many challenges for identifying
these miRNAs, from the extraction procedures to NGS. We
were able to extract total RNA in archived serum samples
of limited availability using a variety of isolation methods
available, thus enabling the sequencing of small RNA and
analysis of circulating, cell-free miRNAs with good per-
formance data. Our analyses showed that TRIzol with and
without addition of glycogen or miRNeasy columns can be
the methods of choice for isolating miRNAs from archived
serum samples.
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